News | May 14, 2015

Combined Blood Pressure and LDL Cholesterol-Lowering Medication Therapy Reduces Harmful Coronary Plaque

Both standard and aggressive treatment provide similar benefit in reducing atherosclerosis

blood pressure, LDL, medication therapy, coronary plaque, SCAI

May 14, 2015 — Combining statins for low-density lipoprotein (LDL) and calcium channel antagonists for blood pressure reduces harmful coronary plaque, according to a study presented at the Society of Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions in San Diego. The study, presented as a late-breaking clinical trial, found aggressive medication therapy does not provide additional benefit compared to standard cholesterol and blood pressure-lowering therapy.

Recent studies have separately shown aggressive treatment of LDL cholesterol with statins and blood pressure control with calcium channel antagonists can control the progression of, or reduce, coronary atherosclerosis. The MILLION study is the first multicenter study to evaluate both strategies simultaneously.

"Aggressively treating cholesterol and blood pressure levels have separately been shown to benefit patients with heart disease, so our study was designed to evaluate whether combined therapy with aggressive or standard targets for reducing LDL cholesterol and blood pressure would provide additional benefit," said Masa-aki Kawashiri, M.D., associate professor of medicine in the Division of Cardiovascular Medicine at Kanazawa University in Kanazawa, Japan, and a study investigator.

Researchers evaluated treatment in a total of 68 patients, including 33 patients who received standard therapy (focused on achieving LDL levels of 100 mg/dL and blood pressure below 140/90 mmHg) and 35 patients treated with aggressive therapy (focused on reducing LDL to 70 mg/dL and blood pressure to 120/70 mmHg). Prior to the study, all of the patients were treated successfully with percutaneous coronary intervention (PCI), and LDL levels greater than 100 mg/dL and had at least one additional coronary artery blockage in addition to the blockage treated by PCI.

Each patient underwent intravascular ultrasonography (IVUS) to measure vessel and plaque volume. After 18-24 months of treatment with blood pressure and cholesterol-lowering medications, follow-up IVUS was conducted. Patients in both groups reached their target blood pressure and LDL levels at the time of follow-up.

The study found both groups had similar rates of reduction in coronary plaque volume. The standard treatment group saw coronary plaque reduced by 9.37 percent while the aggressive group saw an 8.74 percent decrease, on average. However, patients treated with aggressive medication therapy saw more significant decreases in blood pressure (7.5/9.5 mmHg decrease) and LDL cholesterol (6.1 mg/dL decrease) compared with patients receiving standard treatment.

"Patients benefit from similar levels of coronary plaque volume reduction with the standard therapy as with more aggressive treatment," said Kawashiri. "Aggressive LDL cholesterol and blood pressure medication treatment does not provide additional benefit in reducing atherosclerosis. Combined therapy aimed at standard LDL and blood pressure targets provides similar benefit as more aggressive treatment."

Kawashiri reported their study group received research grants from Pfizer Ltd.

For more information: www.scai.org

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo